13th annual AASLD Liver Update with experts from @UHhospitals @metrohealthCLE and @ClevelandClinic #liver14 http://t.co/miwBd4Hjr7

Safe travels to all attendees. See you next year in Vienna for the #EASL meeting and San Francisco for #liver15. #liver14

#ABBV 3D cures 99% GT1b patients with 12 weeks and no need for RBV. Viral kinetics don't predict SVR across the board for GT1 #Liver14

Patient Reported Outcomes (PRO) improve across all domains compared to baseline once SVR12 achieved. rx benefits all from pt angle #Liver14

#harvoni+RBV in decompensated HCV GT1 cirrhotics appears safe and effective. May also improve liver function and drop MELD score. #Liver14

Dr. Fried's hepatitis debrief
Screening of baby boomers is feasible (expensive?)
38% HCV pts don't meet "high or highest priority" #Liver14

Dr. Pantry "post-transplant rx of HCV GT1 with #ABBV 3D+RBV gets 97% SVR12. No rejection &5 got Epo. Immunosuppression manageable" #Liver14

Dr. Pianko "#sovaldi+GS-5816 @100 mg for 12 weeks in GT3 yields 96% SVR12. 25 mg drops SVR12. GT1 have high SVR12 irrespective" #Liver14

Dr. Lawitz "#grazoprevir+#elbasvir +/- RBV for 12-18 wks yields 95% SVR12 in GT1 null responder cirrhotics. RBV may not be needed?" #liver14

Dr rockstroh "77% SVR12 for cirrhotics and 1% #HIV viral breakthrough. Clearly Coinfected cirrhotics need better options" #Liver14

Dr. Rockstroh "#sovaldi+RBV in #HIV/#HCV yields 81% SVR12 in GT1@24 wks, 89%@12 wks in GT2 and 91%@24 wks in GT3. 15% cirrhosis" #Liver14

Important to note that 16 wk duration of PegIFN didn't work well and pts didn't have cirrhosis. Seroreversion occured in combo arm #Liver14

Dr. Petersen "#tenofovir+PegIFN results in 9.0% HBsAg loss @72 weeks. 7 had HBsAG seroreversion. Consolidation therapy needed" #Liver14

@AASLDNews Last day of what has truly been an outstanding #liver14 congrats to outgoing prez @dibiscam & the #AASLD leadership & organizers

Thanks to all who came and shared their thoughts and interests #liver14 http://t.co/bqDewFUplj

First TACE compete response is most robust favorable outcome factor in HCC. Poster 1392 #Liver14 http://t.co/MZrd8tQKfA

Come say hi at the poster session today (if you dare) #Liver14 http://t.co/h5maDxHdpK

Up early (again) for EMW-24 for Prof. Mathurin and Morgan's update on alcoholic hepatitis #Liver14

@BPLBoston in festive mood for #AASLD President members reception tonight #Liver14 http://t.co/CkruRXeenX

Dr. Kottilil " 12 wks of #harvoni yields (49/50) 98% SVR12 in GT1 #HCV/#HIV Coinfected patients.1 HIV viral breakthrough" #NIAID #Liver14

96% rx naive & experienced non cirrhotics achieve SVR12 w/Abbvie 3D. BMI & RBV free combo assoc. with lower likelihood of SVR12. #liver14

Important to note that SVR incr. with RBV addition or 24 weeks not stat. significant. Lively debate about merit of this strategy. #Liver14

Dr. Bourliere 96% GT1 cirrhotics achieve SVR12 w #harvoni. Adding RBV or longer rx to 24 wks ups SVR to 96+ from 90% in experienced #liver14

Dr. Fried "high SVR12 with Abbvie 3D regimen in GT1 cirrhotics. IL-28B TT, null response and GT1a predict lower likelihood of SVR" #Liver14

8 weeks of therapy may not cut it with #sovaldi + GS-5816 for GT 1-6 treatment naive patients without cirrhosis. Need ph. 3 data. #Liver14

Dr. Gane "#solvaldi & GS-5816 at 25 or 100 mg +/- RBV yields high SVR12 rates @ 8 weeks for #HCV GT3 w/o cirrhosis. 2/104 relapses. #Liver14

More strong evidence from China that IL-28B CC GT is strong predictor of spontaneous clearance. May be only reason to test IL-28B #Liver14

Dr. Dietrich presents TRIO SVR12 data. Again, some SVR increment with #sovaldi/#olysio in pre-#harvoni data #Liver14 http://t.co/bSVM6kCsvV

@DonaldJensenMD "HCV-TARGET data on #sovaldi combos. GT1 SVR4 85% (70%cirrhosis/90%no).#sovaldi/#olysio+-RBV SVR4 89%(c87%/no92%) #Liver14

Dr. Hill "meta analysis: SVR reduces all-cause mortality,HCC, tx risk with PegIFN/RBV @5 y. Risk of #HCV re-infection significant" #liver14